Compare CTO & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTO | DRUG |
|---|---|---|
| Founded | 1902 | 2019 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 707.1M |
| IPO Year | N/A | 2020 |
| Metric | CTO | DRUG |
|---|---|---|
| Price | $18.48 | $73.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $21.50 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 224.0K | 104.6K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 8.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $23.18 |
| 52 Week High | $20.25 | $123.75 |
| Indicator | CTO | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 47.88 |
| Support Level | $17.14 | $71.04 |
| Resistance Level | $18.55 | $84.29 |
| Average True Range (ATR) | 0.35 | 4.11 |
| MACD | -0.08 | 0.07 |
| Stochastic Oscillator | 40.17 | 71.51 |
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.